Base Metals Investing Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Base Metals Investing Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
Base Metals Investing Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
base metals investing Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
base metals investing Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
base metals investing Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
base metals investing Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
